Vaxxas Home

Vaxxas Nanopatch™ Technology

Vaccine Application System
Vaxxas Nanopatch Technology
Skip Navigation LinksPages > About Vaxxas > Collaborative Partners

About Vaxxas

Collaborative Partners

Collaborative Partners

Pharma partnerships
Vaxxas is actively seeking partnerships with vaccine companies that have an interest in benefitting from the Nanopatch™ technology. We seek to work in partnership to optimise our delivery technology for the vaccines of interest and help our partners to deliver a cost effective, differentiated, high performance and safe product in the shortest timeframe possible. We believe that Nanopatch™ can:

  1. Enhance the therapeutic and market potential of existing vaccines, and
  2. Provide unprecedented immunogenic response to enable new, next generation vaccines.

Research partnerships
Professor Kendall at The University of Queensland (www.aibn.uq.edu.au/mark-kendall) has collaborated with research institutes worldwide including Oxford University, University of Washington, University of Melbourne and is also in close contact with PATH and the WHO.